Dcb-usa LLC

Development Center for Biotechnology

National Health Research Institutes

Academia Sinica

Obi Pharma Inc.

Jiann-Shiun Lai

Chao-Yang Huang

Ying-Yung Lok

Woan-Eng Chan

Ko-Jiunn Liu

Neng-Yao Shih

Ta-Tung Yuan

Shih-Chong Tsai

Li-Tzong Chen

Shih-Chi Tseng

Chia-Cheng Wu

Chung-Hsiun Wu

Ya-Wei Tsai

I-Ju Chen

Cheng-Der Tony Yu

Yuan-Tsong Chen

Cheng-Chi Wang

Szu-Liang Lai

Chih-Yung Hu

Yi-Chien Tsai

Cheng-Chou Yu

Chuan-Lung Hsu

Young-Sun Lin

Yen-Yu Wu

Chien-Tsun Kuan

Li-Ya Wang

Hung-Ling Wang

Chi-Kuan Chen

Hsien-Yu Tsai

Juo-Yu Huang

Yi-Jiue Tsai

Yi-San Tsai

Yan-Da Lai

Li-Shuang Ai

Po-Yin Lin

An antibody, or an antigen-binding fragment there, binding human ENO1 (GenBank: AAH506421.1) is provided. Methods for treating an ENO1 protein-related disease or disorder, inhibiting cancer invasion and diagnosis of cancer are also provided.

Antibodies specific to alpha-enolase and uses thereof

The present invention relates to an antibody or antigen-binding fragment thereof that bind human vascular endothelial growth factor receptor 2 (VEGFR-2). The present invention also relates to a method for inhibiting VEGFR-2-mediated signaling in a subject in need, a method for treating diseases and/or disorders caused by or related to VEGFR-2 activity and/or signaling in a subject afflicted with the diseases and disorders, a method for treating tumor in a subject afflicted with the tumor, a method for inhibiting cell proliferation of endothelial cells in a subject in need, and a method for detecting human vascular endothelial growth factor receptor in a sample.

Anti-VEGFR antibody and uses thereof

A humanized antibody, or a binding fragment thereof, wherein the humanized antibody binds human ENO1 (GenBank: AAH50642.1), wherein the antibody comprises a light chain variable region (VL) domain comprising a CDR1 having the amino acid sequence LCDR1 (RASENIYSYLT; SEQ ID NO: 6) and a CDR2 having the amino acid sequence LCDR2 (NAKTLPE; SEQ ID NO: 7) and a CDR3 having the amino acid sequence LCDR3 (QHHYGTPYT; SEQ ID NO: 8) and an antibody heavy chain variable region (VH) domain comprising a CDR1 having the amino acid sequence HCDR1 (GYTFTSCVMN; SEQ ID NO: 3), a CDR2 having the amino acid sequence HCDR2 (YINPYNDGTKYNEKFKG; SEQ ID NO: 4) and a CDR3 having the amino acid sequence HCDR3 (EGFYYGNFDN; SEQ ID NO: 5), wherein framework regions in the light chain variable region (VL) domain and the heavy chain variable region (VH) domain comprise amino acid sequences from a human immunoglobulin.

Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy

An anti-granulysin antibody, or an scFv or Fab fragment thereof, capable of binding to an epitope region from R64 to R113 of granulysin and capable of neutralizing an activity of granulysin. The antibody may contain a sequence selected from the sequences of SEQ ID NO:82 to SEQ ID NO:195, or the antibody may contain a sequence selected from the sequences of SEQ ID NO:39 to SEQ ID NO:76. The antibody may be a monoclonal antibody. A method for treating or preventing an unwanted immune response disorder includes administering to a subject in need thereof an effective amount of an anti-granulysin antibody capable of neutralizing the activity of granulysin. The unwanted immune response disorder may be SJS, TEN, or GVHD.

Anti-granulysin antibodies and methods of use thereof

The invention provides antibodies and polypeptides that specifically bind to the glycoprotein D of herpes simplex virus (HSV) and use of the antibodies and polypeptides for treating or diagnosing HSV infections.

Anti-herpes simplex virus antibodies and methods of use thereof

The present invention features a human antibody that specifically binds to human cytomegalovirus (HCMV), its encoding nucleic acid(s), and use of the antibody/nucleic acid(s) in treating HCMV infection.

Anti-human cytomegalovirus antibodies

Growing community of inventors

Taipei, Taiwan

Jiann-Shiun Lai